Rekha Hemrajani - 25 Sep 2024 Form 3 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Director
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Issuer symbol
BIOA
Transactions as of
25 Sep 2024
Net transactions value
$0
Form type
3
Filing time
25 Sep 2024, 16:54:50 UTC
Previous filing
14 Jun 2024
Next filing
04 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIOA Stock Option (Right to Buy) 25 Sep 2024 Common Stock 35,172 $10.27 Direct F1
holding BIOA Stock Option (Right to Buy) 25 Sep 2024 Common Stock 28,497 $8.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on August 15, 2024.
F2 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.